A5090105613- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Childhood Cancer Survivors' Quality of Life
- Blood groups and transfusion
- Retinoids in leukemia and cellular processes
- Platelet Disorders and Treatments
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Systemic Lupus Erythematosus Research
- Complement system in diseases
- Hematological disorders and diagnostics
- Adolescent and Pediatric Healthcare
- Lymphoma Diagnosis and Treatment
- Blood disorders and treatments
- COVID-19 and healthcare impacts
- Frailty in Older Adults
- COVID-19 Clinical Research Studies
- Venous Thromboembolism Diagnosis and Management
- Iron Metabolism and Disorders
- Nutrition and Health in Aging
- Renal Diseases and Glomerulopathies
- Nosocomial Infections in ICU
- Mycobacterium research and diagnosis
- Methemoglobinemia and Tumor Lysis Syndrome
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
2016-2025
Universidad Nacional Autónoma de México
2025
Centro Médico ABC
2021
Abstract Crovalimab is a novel C5 complement inhibitor that enables rapid and sustained inhibition with subcutaneous, low‐volume self‐administration every 4 weeks. COMMODORE 2 (NCT04434092) global, randomized, open‐label, multicenter, phase 3 trial evaluating the non‐inferiority of crovalimab versus eculizumab in patients paroxysmal nocturnal hemoglobinuria not previously treated inhibition. inhibitor‐naive lactate dehydrogenase (LDH) ≥2 × upper limit normal (ULN) were randomized 2:1 to or...
The COVID-19 pandemic is a colossal challenge for global health; nonetheless, specific subgroups face considerably higher risks infection and mortality. Among patients with malignant diseases, those hematologic neoplasms are at risk poor outcomes. objective of this study was to register treatment modifications associated the their short-term consequences in Latin America.Multicenter, prospective, observational, cohort including older than 14 years from centers four countries (Mexico, Peru,...
ABSTRACT Objective Acute lymphoblastic leukemia (ALL) has a higher incidence in Latin America, with adult patients experiencing worse long‐term outcomes despite high complete remission (CR) rates. When treated regimens, 3‐year overall survival (OS) is approximately 20%. However, adopting pediatric‐inspired regimens (PIRs) shown improved outcomes. Methods We performed comparative analysis of Hispanic newly diagnosed Ph‐negative ALL, either PIR, modified CALGB 10403 (mCALGB), or the regimen...
Abstract Background The prevalence of carbapenem-resistant enterobacteria (CRE) in patients with hematological neoplasias varies due to local epidemiology, antimicrobial prophylaxis and types hematopoietic stem cell transplants (HSCT). Colonization by CRE is the main risk factor for infection, which carries a mortality up 65%. This study evaluated colonization acute leukemia (AL) HSCT) within 28 days. Secondary goals included describing bloodstream infections (BSI), Vancomycin-Resistant...
Objective To develop a score for diagnosis of cytopenias from systemic lupus erythematosus (SLE) activity and determine the usefulness bone marrow aspirate biopsy (BMA/BMB) in this population. Methods We conducted cohort study focusing on patients with SLE who underwent BMA/BMB as part evaluation cytopenias. Etiology was categorized into activity, drug-associated toxicity, other diagnoses. devised scoring system, incorporating 5 factors, which were chosen weighed based their relative odds...
Different criteria have been used to diagnose mixed-phenotype acute leukemia (MPAL), which has impacted the number of individuals diagnosed with this pathology. Better outcomes reported when using lymphoblastic (ALL)-type chemotherapy in treatment MPAL.We compared outcome 4 groups patients MPAL. Group 1 included 2008/2016 World Health Organization (WHO) classification; group 2 European for Immunological Characterization Leukemias (EGIL) criteria; 3 either EGIL or WHO and was comprised MPAL...
Mexico and Central America have a high incidence of acute lymphoblastic leukemia (ALL) in adolescents young adults. Historically, this patient group has been treated using adult-based regimens, which entails rate treatment-related mortality poor overall survival (OS). The use the CALGB 10403, pediatric-inspired regimen, proven effective subgroup. Nonetheless, low- middle-income countries (LMICs) may present limited access to standard care treatments implemented elsewhere, warranting need for...
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the clonal expansion of hematopoietic lymphoid progenitors. With new target therapies, survival adults with ALL has improved in past few decades. Unfortunately, there are no large patient series many Latin American countries. Data from Leukemia Workgroup that includes five Mexico City referral centers were used. Survival was estimated for adult patients during 2009-2015. In total, 559 included. The median age 28...
Treatment of paroxysmal nocturnal haemoglobinuria (PNH) includes the monoclonal antibody eculizumab. This randomised, double-blind, multi-national cross-over Phase III study in PNH patients aimed to demonstrate equivalence proposed eculizumab biosimilar SB12 and reference (Soliris, ECU). with lactate dehydrogenase (LDH) ≥1·5× upper limit normal were randomised into treatment sequences SB12-ECU or ECU-SB12. Four weekly infusions 600 mg followed by fortnightly 900 until week 50 (ECU/SB12 at...
Acute promyelocytic leukemia has good prognosis in view of the high complete remission and survival rates achieved with therapies containing all-trans retinoic acid or arsenic trioxide. However, there is a significant risk death during induction due to hemorrhage secondary disseminated intravascular coagulation. This contributed gap patients between developed developing countries. The International Consortium on Promyelocytic Leukemia was created 2005 proposed treatment protocol based...